Clinical Trial Update: Mosunetuzumab and Polatuzumab Vedotin for the Treatment of Patients With Relapsed or Refractory Grade 1-3a Follicular Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating mosunetuzumab and polatuzumab vedotin for relapsed or refractory grade 1-3a follicular lymphoma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma

Drugs mentioned

• Mosunetuzumab (mosunetuzumab)
• polatuzumab vedotin (polatuzumab vedotin)

Snippet

Sponsor: City of Hope Medical Center | Conditions: Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma | Phase 2 | Status: RECRUITING